Literature DB >> 32298504

Hour-specific nomogram for transcutaneous Bilirubin in newborns in Myanmar.

Saneyuki Yasuda1, Hiromi Suzuki2, Yinmon Htun1, Nant San San Aye3, Hnin Oo3, Aung Ko Oo3, Kay Zin Yu3, Khine Shwe Sin3, Susumu Itoh1, Takashi Kusaka1.   

Abstract

BACKGROUND: Neonatal hyperbilirubinemia is a significant health problem in Myanmar, and the rate of kernicterus is also higher than in developed countries. Non-invasive methods for early detection and treatment of hyperbilirubinemia are urgently needed. In this study, we used transcutaneous bilirubin (TcB) measurements to develop an hour-specific TcB nomogram for the effective management of hyperbilirubinemia in Myanmar newborns.
METHODS: The bilirubin levels of neonates born in Central Women Hospital in Yangon, Myanmar were measured three times a day within 72 h after birth using a transcutaneous bilirubinometer. An hour-specific TcB nomogram was created based on the data.
RESULTS: Participants were 512 infants (287 boys, 225 girls) born in Central Women's Hospital in Yangon. The mean (±SD) gestational age was 38.4 ± 1.2 weeks; birthweight was 3078 ± 412 g. A total of 3,039 plots were obtained, and the TcB nomogram was created with smoothed percentile curves (97.5th, 50th, and 2.5th percentiles) for 0-72 h after birth.
CONCLUSIONS: An hour-specific TcB nomogram was successfully created to manage hyperbilirubinemia in Myanmar newborns.
© 2020 Japan Pediatric Society.

Entities:  

Keywords:  Myanmar; hyperbilirubinemia; neonatal jaundice; nomogram; transcutaneous bilirubin

Mesh:

Substances:

Year:  2020        PMID: 32298504     DOI: 10.1111/ped.14251

Source DB:  PubMed          Journal:  Pediatr Int        ISSN: 1328-8067            Impact factor:   1.524


  1 in total

1.  Transcutaneous bilirubin-based screening reduces the need for blood exchange transfusion in Myanmar newborns: A single-center, retrospective study.

Authors:  Hiromi Suzuki; Saneyuki Yasuda; Yinmon Htun; Nant San San Aye; Hnin Oo; Thet Paing Oo; Zaw Lin Htut; Kosuke Koyano; Shinji Nakamura; Takashi Kusaka
Journal:  Front Pediatr       Date:  2022-09-06       Impact factor: 3.569

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.